Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (2120${count})

  • Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022
    Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pronounced neuroimmune dysfunction. Although the disease is very common, no therapy is available...

  • Research Grant, 2022
    Objectively Measuring the Severity of Vocal and Speech-related Symptoms Associated with Parkinson’s Disease

    Study Rationale: The ability to objectively measure vocal symptoms is necessary to better characterize the emergence and development of speech deficits, particularly in the early phases of Parkinson’s...

  • 2022: Accelerated Therapeutics Program, 2022
    Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease

    Study Rationale: Dysfunction in energy-producing structures called mitochondria is a crucial driver of the initiation and progression of Parkinson’s disease (PD). Mitochondria in the cells of people...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022
    Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease

    Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...

  • Winter 2021 RFA: Alpha-synuclein Seed Amplification Assay Program, 2022
    Maximizing the Sensitivity of Seed Amplification Assays Used to Detect Alpha-synuclein Aggregates

    Study Rationale: One characteristic of Parkinson’s disease (PD) is the aggregation of proteins such as alpha-synuclein in the brain. To diagnose PD, it is important to be able to detect such...

  • Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022
    Overcoming Inequity in the Treatment of Parkinson’s Disease: Recognizing and Caring for Underserved Communities in Brazil

    Study Rationale: Brazil has enormous economic and social inequalities. Pesticides, heavy metals and other pollutants can contribute to the development of degenerative conditions such as Parkinson's...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.